Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

Group 1: Axsome Therapeutics - Axsome Therapeutics has a market cap of $3.7 billion, which is considered low compared to its growth potential due to its late-stage pipeline [2] - The company’s approved product, Auvelity, is being tested for treating Alzheimer's disease agitation, with the number of Alzheimer's patients in the U.S. projected to rise from 6.7 million to 14 million by 2060 [2] - Axsome Therapeutics could have five marketed products by the end of next year, indicating substantial upside potential [3] Group 2: CRISPR Therapeutics - The global gene-therapy market is expected to grow at a CAGR of 19.5% until the end of the decade, making CRISPR Therapeutics a potentially lucrative investment [4] - CRISPR Therapeutics has an approved gene-therapy treatment, Casgevy, which is considered cost-effective despite its high price of over $2 million [4] - The approval of Casgevy for treating sickle cell disease and beta-thalassemia is expected to strengthen CRISPR's financials and open up significant growth opportunities [5] Group 3: Pfizer - Pfizer has a low price-to-earnings-to-growth (PEG) ratio of 0.27, indicating an attractive valuation [6] - The company projects annual revenue of $25 billion by 2030 from new product launches, which will offset an estimated $17 billion in lost revenue from expiring patents [7] - Pfizer expects a CAGR of around 10% in revenue growth between 2025 and 2030, alongside a dividend yield of over 6% [8]